These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38976071)

  • 1. Efficacy and safety of apatinib plus immune checkpoint inhibitors and transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma.
    Wu J; Bai X; Yu G; Zhang Q; Tian X; Wang Y
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):340. PubMed ID: 38976071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
    Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
    Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
    Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
    J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.
    Chen S; Yu W; Zhang K; Liu W
    BMC Cancer; 2018 Nov; 18(1):1131. PubMed ID: 30453925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
    Li N; Chen J
    Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
    Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
    J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of transcatheter arterial chemoembolization combined with either
    Li Y; Li H; Hu H; Yuan H; Zhao Y
    J Cancer Res Ther; 2020; 16(7):1691-1697. PubMed ID: 33565518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
    Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
    Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma.
    Li N; Yang P; Fang J
    Clin Res Hepatol Gastroenterol; 2022 Nov; 46(9):102022. PubMed ID: 36089248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
    Wang H; Liu D; Wang C; Yu S; Jin G; Wang C; Zhang B; Zhang D; Shao D
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101869. PubMed ID: 35108656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
    Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
    Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial.
    Hao Y; Xie F; Zhou Y; Li C; Zhang X; Shen J; Yao M; Sun X; Zhou J; Wen T; Peng W
    Trials; 2024 Jul; 25(1):490. PubMed ID: 39030637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.
    Ouyang T; Cao Y; Chen L; Zheng C
    Cardiovasc Intervent Radiol; 2022 Jun; 45(6):780-790. PubMed ID: 35410405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
    Yin L; Liu KC; Lv WF; Lu D; Tan YL; Wang GX; Dai JY; Zhu XH; Jiang B
    Cancer Imaging; 2023 May; 23(1):52. PubMed ID: 37254146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical efficacy and safety of TACE combined with apatinib for advanced hepatocellular carcinoma: A propensity score matching analysis.
    Chen C; Duan X; Shen Y; Li G
    Indian J Cancer; 2024 Apr; 61(2):390-395. PubMed ID: 36861715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma.
    Liu J; Xie S; Duan X; Chen J; Zhou X; Li Y; Li Z; Han X
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):69-76. PubMed ID: 31813003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y; Jia L; Li Y; Cui W; Wang J; Zhang C; Bian C; Wang Z; Lin D; Luo T
    Ann Surg Oncol; 2024 Nov; 31(12):7860-7869. PubMed ID: 39090499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
    Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.